Screening for Depression in Perinatal Settings
Implementing screening in perinatal settings poses a potentially complex set of issues, but screening is nonetheless increasingly being recommended and even mandated. When should screening occur—during pregnancy, postpartum, or both? What instrument should be used? How acceptable is screening to mothers? What difference does screening make to the management of postpartum depression? This chapter presents an evidence-based approach to all aspects of perinatal screening. Over the past 20 years there has been considerable interest in psychiatric disorders arising during the course of pregnancy and following childbirth. Most of the attention has been focused on depressive disorders arising within the first 3 months to 1 year after childbirth, commonly referred to as postnatal or postpartum depression. Pregnancy was once thought to be protective against depressive symptoms; however, women are just as likely to experience depressive symptoms while pregnant as they are during the postpartum period. The mean prevalence of antenatal depression is between 10.7% and 12%, with increasing prevalence and severity through the second and third trimesters. This is comparable with the 10% to 15% of women who develop postpartum depression. While the DSM-IV official recognition of postpartum depression arising after childbirth is confined to a postpartum specifier for those episodes of major depression that have an onset within 4 weeks after delivery, increasing knowledge of depression during the antenatal period has given rise to its equally important early recognition and treatment. Whatever the specifier of postpartum depression in the DSM-IV, depression at this time has been granted considerable importance because of its potential adverse impacts upon child development and maternal morbidity and mortality; and because of the treatment challenges inherent in pregnant and breastfeeding women. Even though the consequences of postpartum depression have been recognized, the illness itself is frequently not identified; it has been estimated that between 50% and 75% of the women suffering from postpartum depression will have it identified and potentially treated. More recent work has focused attention on depression during the course of pregnancy, so-called antenatal depression. However, the validity of measuring depression during pregnancy and in the postpartum period is not clear, especially the boundary between depressive symptoms and clinically significant depressive disorder.